Macomics’ co-founder Professor Jeffrey Pollard celebrated in Highly Cited Researchers 2022
Macomics Ltd, biotech company with world-leading expertise in macrophage biology, is proud to announce that its co-founder Prof. Jeffery Pollard PhD has been honoured with a place in Clarivate’s annual
Highly Cited Researchers 2022 list for the second year running.
Each year, Clarivate celebrates the world’s most influential researchers by identifying those who have been most frequently cited by their peers over the last decade. In 2022, fewer than 7,000, or about 0.1%, of the world’s researchers have earned this exclusive distinction, with the work of those selected spanning 21 research fields.
Prof. Pollard was recognized for his exceptional research influence and designated as part of this elite group for the second year in a row, following the output of multiple highly cited papers that rank in the top 1% of citations for field and year in the Web of Science citation index. The analysis was performed by bibliometric experts and data scientists at the Institute for Scientific Information at Clarivate.
David Pendlebury, Senior Citation Analyst at the Institute for Scientific Information at Clarivate, said:
“Our Highly Cited Researchers are those who have demonstrated significant and broad influence, reflected by multiple highly cited papers that are driving the future of their respective fields of science. Prof. Pollard is a great addition for his visionary research and contributions to the deep understanding of macrophage biology, having established himself as a pioneer in the space through his many years of work.”
Macomics is developing precision medicines to modulate macrophages for the treatment of cancer, based on the pioneering work of its founders Prof. Pollard and Dr Luca Cassetta. An internationally recognized leader in macrophage biology, Prof. Pollard now provides expert consultancy to the company and is Chair of its Scientific Advisory Board. This year, Prof. Pollard was also elected to the highly selective group Academia Europaea (the European Academy, AE) in recognition of his pioneering work in the field of macrophage biology.
Commenting on the achievement, Dr Steve Myatt, CEO of Macomics, said:
“The inclusion of Jeff in the Highly Cited Researchers list for the second-year running is great reflection of the progress that he has achieved in the macrophage field. His work, spanning more than 30 years, has provided the foundations not just for Macomics but also for the wider research field. The insights gained will be of huge benefit to patients in years to come, and to Macomics’ mission to become a leading immuno-oncology company by pioneering macrophage-based therapies for cancer.”
During 2022 Prof. Pollard was also elected to the Academia Europaea (the European Academy, AE) for his visionary and pioneering work in the field of macrophage biology.
Macomics is progressing a diversified portfolio of therapies targeting disease-specific tumour-associated macrophages (‘TAMs’) towards the clinic. Its target discovery platform enables the identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.
The full 2022 Highly Cited Researchers list and executive summary can be found online here.